G. Parmiani

G. Parmiani, C. Gambacorti-Passerini, D. Schendel, 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

Effects of cyclophosphamide and IL-2 on regulatory CD4+ T cell frequency and function in melanoma patients vaccinated with HLA-class I peptides: impact on the antigen-specific T cell response

V. Chiarion-Sileni, M. Maio, B. Vergani, 2013, Cancer Immunology, Immunotherapy.

Cancer-Initiating Cells from Colorectal Cancer Patients Escape from T Cell–Mediated Immunosurveillance In Vitro through Membrane-Bound IL-4

M. Todaro, G. Stassi, C. Doglioni, 2014, The Journal of Immunology.

The early antitumor immune response is necessary for tumor growth

G. Parmiani, C. Maccalli, 2012, Oncoimmunology.

Re-visiting Prehn's hypothesis in the human melanoma system

G. Parmiani, C. Maccalli, 2012 .

Cytokine gene transfer in tumor cells as an approach to antitumor therapy

M. Colombo, G. Parmiani, Stefano Mattei, 1992, International journal of clinical & laboratory research.

Tumor-cell-targeted cytokine gene therapy.

M. Colombo, G. Parmiani, 1991, Immunology today.

Low TCR avidity and lack of tumor cell recognition in CD8+ T cells primed with the CEA-analogue CAP1-6D peptide

P. Romero, G. Parmiani, L. Rivoltini, 2007, Cancer Immunology, Immunotherapy.

Down-regulation of interleukin 6 receptor alpha chain in interleukin 6 transduced melanoma cells causes selective resistance to interleukin 6 but not to oncostatin M.

M. Colombo, C. Toniatti, G. Paonessa, 1995, Cancer research.

Adoptive immunotherapy of a mouse colon carcinoma with recombinant interleukin-2 alone or combined with lymphokine-activated killer cells or tumor-immune lymphocytes

G. Parmiani, M. Rodolfo, C. Salvi, 2005, Cancer Immunology, Immunotherapy.

Selective purging by human interleukin‐2 activated lymphocytes of bone marrows contaminated with a lymphoma line or autologous leukaemic cells

G. Parmiani, S. Siena, C. Gambacorti-Passerini, 1991, British journal of haematology.

An explanation of the variable clinical response to interleukin 2 and LAK cells.

G. Parmiani, 1990, Immunology today.

In vivo interleukin 2-induced activation of lymphokine-activated killer cells and tumor cytotoxic T-cells in cervical lymph nodes of patients with head and neck tumors.

G. Parmiani, C. Gambacorti-Passerini, R. Molinari, 1990, Cancer research.

Role of T cells and tumour necrosis factor in antitumour activity and toxicity of flavone acetic acid.

G. Parmiani, M. Rodolfo, G. Pratesi, 1990, European journal of cancer.

Clonal analysis of cytotoxic T‐lymphocyte response to autologous human metastatic melanoma

A. Anichini, G. Parmiani, G. Fossati, 1985, International journal of cancer.

Growth of human melanoma xenografts is suppressed by systemic angiostatin gene therapy

E. Scanziani, G. Parmiani, P. Vezzoni, 2001, Cancer Gene Therapy.

T lymphocytes can mediate lysis of autologous melanoma cells by multiple mechanisms: Evidence with a single T cell clone

A. Anichini, G. Parmiani, C. Castelli, 2005, Cancer Immunology, Immunotherapy.

Massive ex vivo generation of functional dendritic cells from mobilized CD34+ blood progenitors for anticancer therapy.

A. Anichini, M. Di Nicola, G. Parmiani, 1995, Experimental hematology.

LAG-3 Expression Defines a Subset of CD4+CD25highFoxp3+ Regulatory T Cells That Are Expanded at Tumor Sites

G. Parmiani, C. Castelli, L. Rivoltini, 2010, The Journal of Immunology.

Limited Induction of Tumor Cross-Reactive T Cells without a Measurable Clinical Benefit in Early Melanoma Patients Vaccinated with Human Leukocyte Antigen Class I–Modified Peptides

L. Mariani, V. Chiarion-Sileni, M. Maio, 2012, Clinical Cancer Research.

Autologous dendritic cells derived from CD34+ progenitors and from monocytes are not functionally equivalent antigen-presenting cells in the induction of melan-A/Mart-1(27-35)-specific CTLs from peripheral blood lymphocytes of melanoma patients with low frequency of CTL precursors.

A. Anichini, M. Di Nicola, G. Parmiani, 1997, Cancer research.

Murine granulocytes control human tumor growth in SCID mice

F. Lozupone, F. Belardelli, G. Parmiani, 2000, International journal of cancer.

Melanoma immunotherapy: new dreams or solid hopes?

M. Maio, G. Parmiani, 1996, Immunology today.

Human Tumor-Derived Heat Shock Protein 96 Mediates In Vitro Activation and In Vivo Expansion of Melanoma- and Colon Carcinoma-Specific T Cells1

Jonathan J. Lewis, V. Mazzaferro, P. Srivastava, 2003, The Journal of Immunology.

Carcinoma-Specific T Cells Expansion of Melanoma- and Colon Mediates In Vitro Activation and In Vivo Human Tumor-Derived Heat Shock Protein 96

Jonathan J. Lewis, V. Mazzaferro, P. Srivastava, 2003 .

NKG2D engagement of colorectal cancer‐specific T cells strengthens TCR‐mediated antigen stimulation and elicits TCR independent anti‐tumor activity

P. Robbins, G. Parmiani, C. Castelli, 2003, European journal of immunology.

In vivo reexpression of H-2 antigens in B16 melanoma cells.

P. Lollini, M. Colombo, P. Nanni, 1985, Experimental and Clinical Immunogenetics.

Regression of established liver tumor induced by monoepitopic peptide-based immunotherapy

G. Parmiani, 2005 .

Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE‐3 and presented by HLA‐A1

P. Coulie, Y. Humblet, B. Dréno, 1999, International journal of cancer.

Modulation of multidrug resistance by verapamil or mdr1 anti‐sense oligodeoxynucleotide does not change the high susceptibility to lymphokine‐activated killers in mdr‐resistant human carcinoma (LoVo) line

T. Tsuruo, M. Colombo, R. Supino, 1990, International journal of cancer.

Autologous Versus Allogeneic Cell-Based Vaccines?

G. Parmiani, C. Maccalli, V. Russo, 2011, Cancer journal.

Vaccination of patients with solid tumours.

G. Parmiani, C. Castelli, L. Rivoltini, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

T cell responses in colorectal cancer patients: Evidence for class II HLA‐restricted recognition of shared tumor‐associated antigens

P. Kuppen, S. Andreola, C. Lombardo, 2000, International journal of cancer.

A pilot Phase I study combining peptide-based vaccination and NGR-hTNF vessel targeting therapy in metastatic melanoma

C. Doglioni, A. Corti, G. Parmiani, 2014, Oncoimmunology.

Modified peptides in anti-cancer vaccines: are we eventually improving anti-tumour immunity?

G. Parmiani, R. Valdagni, M. Santinami, 2009, Cancer Immunology, Immunotherapy.

Immunobiology and Use in Clinical Trials Unique Human Tumor Antigens:

G. Parmiani, C. Castelli, L. Novellino, 2022 .

Adoptive transfer of an anti‐MART‐127–35‐specific CD8+ T cell clone leads to immunoselection of human melanoma antigen‐loss variants in SCID mice

F. Lozupone, F. Belardelli, G. Parmiani, 2003, European journal of immunology.

Influence of the donors' clinical status on in vitro and in vivo tumor-cytotoxic activation of interleukin-2-exposed lymphocytes and their circulation in different organs

G. Parmiani, M. Rodolfo, C. Salvi, 2004, Cancer Immunology, Immunotherapy.

In vivo activation of lymphocytes in melanoma patients receiving escalating doses of recombinant interleukin 2

N. Cascinelli, G. Parmiani, C. Gambacorti-Passerini, 1988, International journal of cancer.

Adoptive immunotherapy of cancer with immune and activated lymphocytes: Experimental and clinical studies

M. Colombo, N. Cascinelli, L. Grazioli, 1986, La Ricerca in clinica e in laboratorio.

Vaccination of Stage IV patients with allogeneic IL-4- or IL-2-gene-transduced melanoma cells generates functional antibodies against vaccinating and autologous melanoma cells

M. Colombo, M. Maio, G. Parmiani, 2002, Cancer Immunology, Immunotherapy.

Human melanoma-reactive CD4+ and CD8+ CTL clones resist Fas ligand-induced apoptosis and use Fas/Fas ligand-independent mechanisms for tumor killing.

M. Colombo, G. Parmiani, C. Castelli, 1998, Journal of immunology.

Mechanisms for Tumor Killing and Use Fas / Fas Ligand-Independent CTL Clones Resist Fas Ligand-Induced Apoptosis + and CD 8 + Human Melanoma-Reactive CD 4

M. Colombo, G. Parmiani, C. Castelli, 1998 .

Phenotypic profile of clones from early cultures of human metastatic melanomas and its modulation by recombinant interferon γ

A. Anichini, G. Parmiani, R. Mortarini, 1986, International journal of cancer.

Classes I and II HLA and melanoma-associated antigen expression and modulation on melanoma cells isolated from primary and metastatic lesions.

D. Taramelli, D. Delia, S. Ferrone, 1986, Cancer research.

Human melanoma cells with high susceptibility to cell‐mediated lysis can be identified on the basis of icam‐1 phenotype, vla profile and invasive ability

R. Supino, A. Anichini, G. Parmiani, 1990, International journal of cancer.

Multiple VLA antigens on a subset of melanoma clones.

A. Anichini, G. Parmiani, R. Mortarini, 1990, Human immunology.

Induction and functional characterization of β 2‐microglobulin (β2‐μ)‐free HLA class I heavy chains expressed by β2‐μ‐deficient human FO‐1 melanoma cells

S. Ferrone, G. Parmiani, F. Arienti, 1998 .

HLA Class II Antigens on Melanoma Cells

A. Anichini, G. Parmiani, C. Castelli, 1990 .

Immune response to autologous human melanoma: implication of class I and II MHC products.

J. Kirkwood, D. Taramelli, A. Anichini, 1986, Biochimica et biophysica acta.

Comparative assessment of TCRBV diversity in T lymphocytes present in blood, metastatic lesions, and DTH sites of two melanoma patients vaccinated with an IL-7 gene-modified autologous tumor cell vaccine

D. Schadendorf, P. Möller, G. Nicolini, 2002, Cancer Gene Therapy.

Therapeutic use of a long-term cytotoxic T cell line recognizing a common tumour-associated antigen: The pattern of in vitro reactivity predicts the in vivo effect on different tumours

G. Parmiani, M. Rodolfo, C. Salvi, 2005, Cancer Immunology, Immunotherapy.

Phenotypic and functional analysis of lymphocytes infiltrating paediatric tumours, with a characterization of the tumour phenotype

G. Parmiani, C. Gambacorti-Passerini, L. Rivoltini, 2005, Cancer Immunology, Immunotherapy.

Lysis by interleukin 2-stimulated tumor-infiltrating lymphocytes of autologous and allogeneic tumor target cells

G. Parmiani, C. Gambacorti-Passerini, M. Radrizzani, 2004, Cancer Immunology, Immunotherapy.

Adoptive Immunotherapy of Melanoma with Interleukin-2 and Lymphocytes

N. Cascinelli, G. Parmiani, M. Santinami, 1993 .

Efficacy and safety of ipilimumab in patients with pre-treated, uveal melanoma.

P. Ascierto, E. Simeone, P. Queirolo, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

beta2-Microglobulin mutations, HLA class I antigen loss, and tumor progression in melanoma.

D. Hicklin, S. Ferrone, G. Parmiani, 1998, The Journal of clinical investigation.

Adoptive immunotherapy of advanced melanoma patients with interleukin-2 (IL-2) and tumor-infiltrating lymphocytes selected in vitro with low doses of IL-2

N. Cascinelli, G. Parmiani, C. Gambacorti-Passerini, 1993, Cancer Immunology, Immunotherapy.

Loco-regional immunotherapy with recombinant interleukin-2 and adherent lymphokine-activated killer cells (A-LAK) in recurrent glioblastoma patients

G. Broggi, A. Silvani, A. Salmaggi, 1994, Cancer Immunology, Immunotherapy.

Factors, including transforming growth factor β, released in the glioblastoma residual cavity, impair activity of adherent lymphokine-activated killer cells

A. Silvani, G. Parmiani, L. Rivoltini, 1993, Cancer Immunology, Immunotherapy.

A B7‐1‐transfected human melanoma line stimulates proliferation and cytotoxicity of autologous and allogeneic lymphocytes

M. Colombo, J. Sulé-Suso, G. Parmiani, 1995, European journal of immunology.

Differences between in Vivoand in Vitro Activation of Cancer Patient Lymphocytes by Recombinant Inter leukin 2 : Possible Role for Lymphokine-activated Killer Cell Infusion in the in F / vo-induccd Activation 1

N. Cascinelli, G. Parmiani, C. Gambacorti-Passerini, 2006 .

Differences between in vivo and in vitro activation of cancer patient lymphocytes by recombinant interleukin 2: possible role for lymphokine-activated killer cell infusion in the in vivo-induced activation.

N. Cascinelli, G. Parmiani, C. Gambacorti-Passerini, 1989, Cancer research.

Potential therapeutic use of autologous human lymphocytes in metastatic melanoma: in vivo interleukin 2-activated peripheral blood lymphocytes and in vitro activated peripheral blood and tumor-infiltrating lymphocytes.

N. Cascinelli, G. Parmiani, C. Gambacorti-Passerini, 1988, Advances in experimental medicine and biology.

Differences in frequency distribution of HLA-A2 subtypes between North American and Italian white melanoma patients: relevance for epitope specific vaccination protocols.

F. Marincola, G. Parmiani, C. Castelli, 1996, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

Immunodominance in the T-cell response to multiple non-H-2 histocompatibility antigens. V. Chromosomal mapping of the immunodominant cytotoxic T-cell target-1 (CTT-1)

P. D’Eustachio, M. Colombo, G. Parmiani, 2004, Immunogenetics.

Mouse tumors are heterogeneous in their susceptibility to syngeneic lymphokine-activated killer cells and delineate functional subsets in such effectors

L. Grazioli, G. Parmiani, M. Rodolfo, 2005, Cancer Immunology, Immunotherapy.

PTPRK negatively regulates transcriptional activity of wild type and mutated oncogenic beta-catenin and affects membrane distribution of beta-catenin/E-cadherin complexes in cancer cells.

S. Pilotti, F. Perrone, G. Parmiani, 2008, Cellular signalling.

T‐cell‐receptor engagement and tumor ICAM‐1 up‐regulation are required to by‐pass low susceptibility of melanoma cells to autologous CTL‐mediated lysis

A. Mantovani, S. Alberti, A. Anichini, 2009, International journal of cancer.

The Italian Network for Tumor Biotherapy (NIBIT). Sharing Visions, Goals and Efforts at European Level

M. Maio, G. Parmiani, E. Fonsatti, 2008, Tumori.

The Italian Network for Tumor Biotherapy (NIBIT): Getting together to push the field forward

P. Ascierto, M. Colombo, P. Queirolo, 2008, Journal of Translational Medicine.

Cytokine‐mediated modulation of HLA‐class II, ICAM‐1, LFA‐3 and tumor‐associated antigen profile of melanoma cells. comparison with anti‐proliferative activity by RIL1‐β, RTNF‐α, RIFN‐γ, RIl4 and their combinations

A. Anichini, G. Parmiani, R. Mortarini, 1990 .

In vitro anti‐tumor activity of eosinophils from cancer patients treated with subcutaneous administration of interleukin 2. Role of interleukin 5

M. Colombo, A. Santoro, K. Takatsu, 1993, International journal of cancer.

Altered peptide ligands of tumor T-cell epitopes: implications for more effective vaccine therapy in human neoplasia

G. Parmiani, L. Rivoltini, M. Carrabba, 2003 .

Immunological markers and clinical outcome of advanced melanoma patients receiving ipilimumab plus fotemustine in the NIBIT-M1 study

M. Maio, G. Parmiani, D. Giannarelli, 2016, Oncoimmunology.

Soluble human LAG-3 molecule amplifies the in vitro generation of type 1 tumor-specific immunity.

G. Parmiani, C. Castelli, L. Rivoltini, 2006, Cancer research.

Lymphotoxin gene expression by melanocytes and melanoma cell lines and persistence of unspliced mRNA

M. Colombo, G. Parmiani, C. Melani, 1993, FEBS letters.

Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study.

P. Ascierto, A. Testori, E. Simeone, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Human Plasmacytoid Dendritic Cells Interact with gp96 via CD91 and Regulate Inflammatory Responses1

A. Villa, G. Parmiani, P. Della Mina, 2008, The Journal of Immunology.

Lack of suppressive activity of human primary melanoma cells on the activation of autologous lymphocytes

D. Taramelli, G. Parmiani, A. Mazzocchi, 2004, Cancer Immunology, Immunotherapy.

Loss of Heterozygosity of Dq Alpha Gene in Human Malignant Melanoma

G. Parmiani, C. Castelli, M. Sensi, 1989, Tumori.

LOSS OF POLYMORPHIC RESTRICTION FRAGMENTS OF CLASS I AND CLASS II MHC GENES IN A MALIGNANT MELANOMA

G. Ferrara, P. Radice, M. Pierotti, 1986, Journal of immunogenetics.

NKG2D-Mediated Antitumor Activity by Tumor-Infiltrating Lymphocytes and Antigen-Specific T-Cell Clones Isolated from Melanoma Patients

D. Nonaka, G. Parmiani, A. Piris, 2007, Clinical Cancer Research.

NKG 2 D-Mediated AntitumorActivity by Tumor-Infiltrating Lymphocytes and Antigen-Specific T-Cell Clones Isolated fromMelanoma Patients

D. Nonaka, G. Parmiani, A. Piris, 2007 .

Human CD4 lymphocytes specifically recognize a peptide representing the fusion region of the hybrid protein pml/RAR alpha present in acute promyelocytic leukemia cells.

P. Pandolfi, P. Pelicci, G. Parmiani, 1993, Blood.

Chemokine Receptor 7, A New Player in Regulating Apoptosis of CD8+ T Cells in Cancer Patients

G. Parmiani, C. Castelli, L. Rivoltini, 2005, Clinical Cancer Research.

Inflammatory Responses with gp96 via CD91 and Regulate Human Plasmacytoid Dendritic Cells Interact

A. Villa, G. Parmiani, C. Castelli, 2008 .

Interleukin-6 expression in human neutrophil and eosinophil peripheral blood granulocytes.

A. Carè, M. Colombo, G. Parmiani, 1993, Blood.

myb That Express c-Oligodeoxynucleotides in Colon Adenocarcinoma Cell Lines Antisense myb Inhibition of Proliferation by c-Updated Version

M. Colombo, B. Calabretta, G. Parmiani, 2006 .

Antigen-specific immunity in neuroblastoma patients: antibody and T-cell recognition of NY-ESO-1 tumor antigen.

P. Dalerba, L. Old, C. Lombardo, 2003, Cancer research.

An in vivo model to compare human leukocyte infiltration in carcinoma xenografts producing different chemokines

S. Ménard, M. Colombo, G. Parmiani, 1995, International journal of cancer.

Expression of cytokine/growth factors and their receptors in human melanoma and melanocytes

M. Herlyn, M. Colombo, G. Parmiani, 1994, International journal of cancer.

T Cell Receptor (TCR) Structure of Autologous Melanoma-reactive Cytotoxic T Lymphocyte (CTL) Clones: Tumor-lnfiltrating Lymphocytes Overexpress In Vivo the TCR f3 Chain Sequence Used by an HLA-A2-restricted and Melanocyte-lineage-specific

M. Herlyn, G. Nicolini, A. Anichini, 2003 .

Down-regulation of SPARC/osteonectin/BM-40 expression in methylcholanthrene-induced fibrosarcomas and in Kirsten-MSV transformed fibroblasts.

M. Colombo, G. Parmiani, D. Galasso, 1991, European journal of cancer.

Isolation perfusion in extracorporeal circulation with interleukin-2 and lymphokine-activated killer cells in the treatment of in-transit metastases from limb cutaneous melanoma

N. Cascinelli, G. Parmiani, N. Santoro, 1995, Annals of Surgical Oncology.

Gene transfer in tumor therapy.

R. Foà, A. Guarini, G. Forni, 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

Immunotherapy of cancer with interleukin-2 and lymphocytes (LAK or TIL).

G. Parmiani, 1992, Pharmacological research.

Vaccination with T Cell-Defined Antigens: Biological Basis and Clinical Applications

G. Parmiani, 2001 .

Immunological gene therapy with ex vivo gene-modified tumor cells: a critique and a reappraisal.

G. Parmiani, M. Rodolfo, C. Melani, 2000, Human gene therapy.

Cytotoxic T cells directed to tumor antigens not expressed on normal melanocytes dominate HLA-A2.1-restricted immune repertoire to melanoma.

A. Anichini, G. Parmiani, R. Mortarini, 1996, Journal of immunology.

Gene transfer into human dendritic antigen-presenting cells by vaccinia virus and adenovirus vectors.

A. Anichini, M. Di Nicola, G. Sutter, 1998, Cancer gene therapy.

Expression of MAGE genes in primary and metastatic cutaneous melanoma

Rika Deraemaecker, Stefan Suciu, Marie Marchand, 1995, International journal of cancer.

Gene therapy in melanoma.

G. Parmiani, F. Belli, C. Melani, 2001, Methods in molecular medicine.

In vivo characterization of a doxorubicin resistant B16 melanoma cell line.

R. Supino, F. Formelli, G. Parmiani, 1986, British Journal of Cancer.

Reactivity of human lymphocyte clones to autologous metastatic melanoma cells.

A. Anichini, G. Parmiani, A. Mazzocchi, 1988, Advances in experimental medicine and biology.

Allostimulation of patients' lymphocytes generates both T and NK-like cells cytotoxic for autologous melanoma.

D. Taramelli, D. Delia, G. Parmiani, 1985, British Journal of Cancer.

Recognition of melanoma-derived antigens by CTL: possible mechanisms involved in down-regulating anti-tumor T-cell reactivity.

F. Marincola, E. Appella, C. Geisler, 1998, Critical reviews in immunology.

Proliferative and/or cytotoxic activity of lymphocyte clones to autologous human melanoma

A. Anichini, G. Parmiani, A. Mazzocchi, 1988, International journal of cancer.

Clonal analysis of the cytolytic T-cell response to human tumors.

A. Anichini, G. Parmiani, G. Fossati, 1987, Immunology today.

Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients.

M. Colombo, G. Parmiani, M. Santinami, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Cell retargeting by bispecific monoclonal antibodies. Evidence of bypass of intratumor susceptibility to cell lysis in human melanoma.

F. Malavasi, A. Anichini, M. Mariani, 1992, The Journal of clinical investigation.

Active immunization of metastatic melanoma patients with interleukin-4 transduced, allogeneic melanoma cells. A phase I-II study.

R. Foà, M. Colombo, N. Cascinelli, 1994, Human gene therapy.

LAG-3 Expression Defines a Subset of CD4+CD25highFoxp3+ Regulatory T Cells That Are Expanded at Tumor Sites

G. Parmiani, C. Castelli, L. Rivoltini, 2010, The Journal of Immunology.

Cellular immune response against autologous human malignant melanoma: are in vitro studies providing a framework for a more effective immunotherapy?

A. Anichini, G. Parmiani, G. Fossati, 1990, Journal of the National Cancer Institute.

Disulfide‐linked surface molecules of monoclonal antigen‐specific suppressor T cells: evidence for T cell receptor structures

P. Ricciardi-Castagnoli, M. Pierotti, L. Adorini, 1985, European journal of immunology.

Human tumor-released microvesicles promote the differentiation of myeloid cells with transforming growth factor-beta-mediated suppressive activity on T lymphocytes.

A. Villa, G. Parmiani, S. Fais, 2006, Cancer research.

Expression of alien h‐2 specificities on a chemically induced balb/c fibrosarcoma

G. Parmiani, A. Meschini, G. Invernizzi, 1977 .

MULTIPLE FOREIGN NON‐H‐2 DETERMINANTS ON THE SURFACE OF A CHEMICALLY‐INDUCED MURINE SARCOMA *

G. Parmiani, A. Meschini, G. Invernizzi, 1977, Journal of immunogenetics.

International Meeting “Immunotherapy of Cancer: Challenges and Needs”

F. Marincola, F. Belardelli, M. Ferrantini, 2007, Cancer Immunology, Immunotherapy.

Human Lymphocyte Activation Gene-3 Molecules Expressed by Activated T Cells Deliver Costimulation Signal for Dendritic Cell Activation1

G. Parmiani, C. Castelli, L. Rivoltini, 2008, The Journal of Immunology.

Cell Activation Deliver Costimulation Signal for Dendritic Molecules Expressed by Activated T Cells Human Lymphocyte Activation Gene-3 Parmiani and

G. Parmiani, C. Castelli, L. Rivoltini, 2008 .

Induction of autologous human melanoma killer lymphocytes by allostimulation

G. Parmiani, G. Fossati, 1985 .

Generation of TSTA diversity

M. Pierotti, G. Parmiani, 1983, Cancer Immunology, Immunotherapy.

Tumor immunity as autoimmunity: tumor antigens include normal self proteins which stimulate anergic peripheral T cells.

G. Parmiani, Giorgio Parmiani, 1993, Immunology today.

Cell surface antigens of chemically induced fibrosarcomas: detection by a monoclonal antibody of a tumor-restricted Mr 12,000 protein gag antigen encoded by a dual-tropic murine leukemia virus.

M. Borrello, P. Radice, M. Pierotti, 1985, Cancer research.

Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. V. H‐2 associativity of variant‐specific antigens

J. Van Snick, G. Parmiani, A. van Pel, 1982, European journal of immunology.

Alien Histocompatibility Determinants on the Cell Surface of Sarcomas Induced by Methylcholanthrene. II. in Vitro Serological Studies 1

G. Parmiani, G. Invernizzi, G. Carbone, 1977, Tumori.

Immune‐depressive effect of urethan on the homograft response in mice

G. Parmiani, 1970, International journal of cancer.

Role of the Immune System in the Growth of an Isotransplanted Urethan-Induced Lymphosarcoma

G. Parmiani, G. Carbone, 1969, Tumori.

TCR Variable Regions T Lymphocyte Subsets Expressing Distinct Molecules in Metastatic Melanoma Patients' Differential Loss of T Cell Signaling

A. Anichini, G. Parmiani, C. Vegetti, 1999 .

Interleukin-6 expression in human neutrophil and eosinophil peripheral blood granulocytes

A. Carè, M. Colombo, G. Parmiani, 1993 .

Genetic modification of a carcinoma with the IL‐4 gene increases the influx of dendritic cells relative to other cytokines

M. Colombo, A. Stoppacciaro, G. Parmiani, 1997, European journal of immunology.

BIOCHEMICAL ANALYSIS OF A PUBLIC H‐2 SPECIFICITY REVEALED BY AN ANOMALOUS REACTION OF AN ALLOANTISERUM WITH A CHEMICALLY INDUCED C57BL/10 FIBROSARCOMA

M. Pierotti, D. Ballinari, L. Grazioli, 1982, Journal of immunogenetics.

Cytotoxic T-lymphoc ' te clones from different patients display limited T-cell-receptor variable-region gene usage in HLA-A 2-restricted recognition of the melanoma antigen MelanA / MART-1

C. Farina, G. Nicolini, A. Anichini, 2005 .

Type I interferon gene transfer sensitizes melanoma cells to apoptosis via a target activity on mitochondrial function.

P. Matarrese, L. Di Biase, F. Belardelli, 2002, The American journal of pathology.

Multiple sub‐sets of Cd4+ and Cd8+ cytotoxic T‐cell clones directed to autologous human melanoma identified by cytokine profiles

A. Anichini, G. Parmiani, R. Mortarini, 1994, International journal of cancer.

Expansion of Major Histocompatibility Complex-Restricted Antimelanoma Cytotoxic T-Cell Lymphocyte Clones with Identical T-Cell Receptor from Tumor-Infiltrating Lymphocytes

G. Nicolini, A. Anichini, G. Parmiani, 1992, Journal of immunotherapy : official journal of the Society for Biological Therapy.

Two autologous melanoma‐specific and MHC‐restricted human T cell clones with identical intra‐tumour reactivity do not share the same TCR Vα and Vβ gene families

A. Anichini, G. Parmiani, R. Mortarini, 1991 .

Tumor antigens recognized by T cells and antibodies

G. Parmiani, Y. Kawakami, H. Stauss, 2003 .

Interleukin-2 gene-transduced human melanoma cells efficiently stimulate MHC-unrestricted and MHC-restricted autologous lymphocytes.

M. Colombo, N. Cascinelli, A. Anichini, 1994, Human gene therapy.

Suboptimal activation of CD8(+) T cells by melanoma-derived altered peptide ligands: role of Melan-A/MART-1 optimized analogues.

G. Parmiani, M. Maeurer, C. Castelli, 2003, Cancer research.

Optimized Analogues Altered Peptide Ligands : Role of MelanA / MART-1 T Cells by Melanoma-derived + Suboptimal Activation of CD 8 Updated Version

G. Parmiani, M. Maeurer, C. Castelli, 2003 .

Heterogeneity in human melanoma cell adhesion to cytokine activated endothelial cells correlates with VLA-4 expression.

A. Mantovani, S. Bernasconi, E. Dejana, 1991, Cancer research.

CCN3/nephroblastoma overexpressed matricellular protein regulates integrin expression, adhesion, and dissemination in melanoma.

A. Carbone, G. Parmiani, N. Lazar, 2008, Cancer research.

CCN3/nephroblastoma overexpressed matricellular protein regulates integrin expression, adhesion, and dissemination in melanoma.

A. Carbone, G. Parmiani, N. Lazar, 2008, Cancer Research.

The inhibition of lymphocyte stimulation by autologous human metastatic melanoma cells correlates with the expression of HLA‐DR antigens on the tumor cells

D. Taramelli, G. Parmiani, A. Balsari, 1984, International journal of cancer.

Lack of cross-resistance of a doxorubicin-resistant B16 melanoma line with 4'-deoxy-4'-iodo-doxorubicin

R. Supino, M. Mariani, E. Prosperi, 2004, Cancer Chemotherapy and Pharmacology.

Characterization of a doxorubicin-resistant murine melanoma line: studies on cross-resistance and its circumvention.

R. Supino, M. Mariani, E. Prosperi, 1986, British Journal of Cancer.

Overexpression of the T-cell receptor beta-chain variable region TCRBV14 in HLA-A2-matched primary human melanomas.

A. Anichini, G. Parmiani, S. Rao, 1995, Cancer research.

Primary but not metastatic human melanomas expressing dr antigens stimulate autologous lymphocytes

D. Taramelli, S. Andreola, G. Parmiani, 1984, International journal of cancer.

Role of the a$ÃŸiIntegrin Receptor in the Proliferative Response of Quiescent Human Melanoma Cells to Fibronectin1

Roberta, A. Santoni, A. Anichini, 2006 .

Clonal expansion of T lymphocytes in human melanoma metastases after treatment with a hapten-modified autologous tumor vaccine.

C. Farina, G. Nicolini, A. Anichini, 1997, The Journal of clinical investigation.

Role of the α5β1 Integrin Receptor in the Proliferative Response of Quiescent Human Melanoma Cells to Fibronectin

A. Santoni, A. Anichini, G. Parmiani, 1992 .

International Meeting on Cancer Vaccines

J. Schlom, F. Belardelli, M. Ferrantini, 2004, Cancer Research.

Lack of T-cell-mediated recognition of the fusion region of the pml/RAR-alpha hybrid protein by lymphocytes of acute promyelocytic leukemia patients.

G. Parmiani, C. Gambacorti-Passerini, K. Blaser, 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

Tumor-released microvesicles as vehicles of immunosuppression.

G. Parmiani, L. Rivoltini, P. Filipazzi, 2007, Cancer research.

Effect of Prolonged Subcutaneous Administration of Interleukin-2 on the Orcadian Rhythms of Cortisol and Beta-Endorphin in Advanced Small Cell Lung Cancer Patients

G. Parmiani, L. Rivoltini, S. Viviani, 1991, Tumori.

Doxorubicin cellular pharmacokinetics and DNA breakage in a multi-drug resistant B16 melanoma cell line.

G. Capranico, R. Supino, M. Mariani, 1988, British Journal of Cancer.

Type I consensus interferon (CIFN) gene transfer into human melanoma cells up-regulates p53 and enhances cisplatin-induced apoptosis: implications for new therapeutic strategies with IFN-alpha

P. Matarrese, F. Belardelli, P. Sestili, 2000, Gene Therapy.

Genetic Unresponsiveness to a Murine Fibrosarcoma Determined by the Host Genetic Environment but not by Lymphocyte Precursor Genotype

M. Colombo, G. Parmiani, M. Rodolfo, 1985, Tumori.

In vitro detection of cell‐mediated immunity to individual tumor‐specific antigens of chemically induced BALB/c fibrosarcomas

M. Colombo, G. Parmiani, M. Sensi, 1983, International journal of cancer.

Active immunization of metastatic melanoma patients with interleukin-2-transduced allogeneic melanoma cells: evaluation of efficacy and tolerability

M. Colombo, N. Cascinelli, A. Cattelan, 1997, Cancer Immunology, Immunotherapy.

Human allogeneic melanoma‐reactive T‐helper lymphocyte clones: Functional analysis of lymphocyte‐melanoma interactions

G. Ferrara, M. Herlyn, M. Herlyn, 1991, International journal of cancer.

Regulated expression of vascular cell adhesion molecule-1 in human malignant melanoma.

S. Bernasconi, N. Jonjić, A. Anichini, 1992, The American journal of pathology.

The Role of Cytokines in the Modulation of Cell Surface Antigens of Human Melanoma

A. Anichini, G. Parmiani, R. Mortarini, 1993, The International journal of biological markers.

Increasing immunogenicity of cancer vaccines to improve their clinical outcome

G. Parmiani, C. Maccalli, C. Cimminiello, 2013, Expert review of vaccines.

Cytokine-based gene therapy of human tumors. An overview.

M. Colombo, N. Cascinelli, J. Sulé-Suso, 1996, Folia biologica.

Generation and partial characterization of melanoma sublines resistant to lymphokine activated killer (LAK) cells. Relevance to doxorubicin resistance

R. Supino, G. Parmiani, C. Gambacorti-Passerini, 1989, International journal of cancer.

Potentiation of adoptive immunotherapy by cis‐diamminedichloroplatinum(II), but not by doxorubicin, on a disseminated mouse lymphoma and its association with reduction of tumor burden

F. Formelli, G. Parmiani, M. Sensi, 1988, International journal of cancer.

A new Procedure for Large Scale Production and Freezing of Lymphokine Activated Killer (LAK) Cells to be used in Adoptive Immunotherapy of Cancer

N. Cascinelli, G. Parmiani, C. Gambacorti-Passerini, 1988, Tumori.

The high lysability by lak cells of colon‐carcinoma cells resistant to doxorubicin is associated with a high expression of ICAM‐1, LFA‐3, NCA and a less‐differentiated phenotype

M. Colombo, G. Cattoretti, G. Parmiani, 1991, International journal of cancer.

Tumour-associated transplantation antigens of chemically induced sarcomata cross reacting with allogeneic histocompatibility antigens

G. Parmiani, G. Invernizzi, 1975, Nature.

Interaction of Cytotoxic T Lymphocytes with Autologous Melanoma: Role of Adhesion Molecules and β1 Integrins

A. Anichini, G. Parmiani, R. Mortarini, 1993 .

T-cell recognition of melanoma-associated antigens.

G. Parmiani, C. Castelli, L. Rivoltini, 2000, Journal of cellular physiology.

Erratum: In vitro anti-tumor activity of eosinophils from cancer patients treated with subcutaneous administration of interleukin 2. Role of interleukin 5 (Int. J. Cancer, 54, 8-15 (1993))

M. Colombo, A. Santoro, K. Takatsu, 1993 .

Cancer patients' lymphocytes contain CD3+CD4+cells that proliferate in response to autologous tumor cells in the presence of exogenous low-dose interleukin-2 and autologous accessory cells

S. Andreola, M. Quaia, E. Galligioni, 2005, Cancer Immunology, Immunotherapy.

Somatic gene therapy of human melanoma: preclinical studies and early clinical trials.

M. Colombo, G. Parmiani, 1995, Melanoma research.

Occurrence of resistance to retinoic acid in the acute promyelocytic leukemia cell line NB4 is associated with altered expression of the pml/RAR alpha protein.

P. Pelicci, G. Sozzi, F. Formelli, 1993, Blood.

Transplacental Toxicity and Carcinogenesis Studies in Rats with Hexamethylenetetramine

G. Parmiani, J. Cabral, G. Porta, 1970, Tumori.

Role of the alpha 5 beta 1 integrin receptor in the proliferative response of quiescent human melanoma cells to fibronectin.

A. Santoni, A. Anichini, G. Parmiani, 1992, Cancer research.

Defining the critical hurdles in cancer immunotherapy

Zhigang Tian, Sylvia Janetzki, Cedrik M Britten, 2011, Journal of Translational Medicine.

Growth Inhibition of Murine Colonic Adenocarcinoma by Tumor Immune but not by IL-2-Activated or Alloactivated Lymphocytes

G. Parmiani, M. Rodolfo, Giorgio Parmiani, 1987, Tumori.

Alloreactivity and tumor antigens: generation of syngeneic antilymphoma killer lymphocytes by alloimmunization of mice with normal cells.

G. Parmiani, M. Sensi, M. Parenza, 1983, Journal of the National Cancer Institute.

Cross‐reactions between tumor cells and allogeneic normal tissues. inhibition of a syngeneic lymphoma outgrowth in h‐2 and non‐h‐2 alloimmune balb/c mice

M. Colombo, M. Pierotti, D. Ballinari, 1982, International journal of cancer.

Increased Oncogenic Effect of a Low Dose of Methylcholanthrene in Immunodepressed Mice

G. Parmiani, G. Carbone, 1971, Tumori.

Human melanocytes and melanomas express novel mRNA isoforms of the tyrosinase-related protein-2/DOPAchrome tautomerase gene: molecular and functional characterization.

A. Anichini, G. Parmiani, A. Napolitano, 2000, The Journal of investigative dermatology.

Cutaneous melanoma in childhood and adolescence shows frequent loss of INK4A and gain of KIT.

S. Manoukian, S. Pilotti, A. Ferrari, 2009, The Journal of investigative dermatology.

Treatment of a low immunogenic experimental tumour with alloactivated or tumour-immune lymphocytes.

M. Colombo, L. Grazioli, G. Parmiani, 1987, Biochimica et biophysica acta.

Mitogenic activity of fibronectin and laminin on human melanoma is mediated by β1 integrins: 251

A. Santoni, A. Anichini, G. Parmiani, 1993 .

Effect of proton pump inhibitor pretreatment on resistance of solid tumors to cytotoxic drugs.

F. Lozupone, A. Molinari, F. Belardelli, 2004, Journal of the National Cancer Institute.

IMPAIRED H‐2 EXPRESSION IN B 16 MELANOMA VARIANTS

P. Lollini, M. Colombo, P. Nanni, 1983, Journal of immunogenetics.

The undefined relationship between tumor antigens and histocompatibility antigens on cancer cells

G. Parmiani, G. Fossati, G. Porta, 1980, La Ricerca in clinica e in laboratorio.

Analysis of the cellular immune response to and adoptive immunotherapy of a BALB/c lymphoma that cross-reacts with normal DBA/2 cells

L. Grazioli, G. Parmiani, M. Sensi, 2004, Cancer Immunology, Immunotherapy.

Adoptive immunotherapy of a BALB/c lymphoma by syngeneic anti-DBA/2 immune lymphoid cells: Characterization of the effector population and evidence for the role of the host's non-T cells

M. Colombo, G. Parmiani, M. Parenza, 2004, Cancer Immunology, Immunotherapy.

Lysis of autologous human melanoma cells by in vitro allosensitized peripheral blood lymphocytes

D. Taramelli, G. Parmiani, M. Sensi, 2004, Cancer Immunology, Immunotherapy.

Passive adoptive immunotherapy of low‐immunogenic BALB/C lymphoma by syngeneic alloimmune T lymphocytes

M. Colombo, G. Parmiani, I. Arioli, 1984, International journal of cancer.

Systemic administration of autologous, alloactivated helper-enriched lymphocytes to patients with metastatic melanoma of the lung

D. Taramelli, N. Cascinelli, G. Parmiani, 2004, Cancer Immunology, Immunotherapy.

DBA/2‐like minor histocompatibility antigens on a BALB/c lymphoma. A balb/c anti‐DBA/2 serum which lyses the tumor and blocks balb/c anti‐tumor and anti‐DBA/2 effectors

M. Borrello, D. Ballinari, L. Grazioli, 1985, International journal of cancer.

ALIEN ANTIGENS ON TUMOUR CELLS REVISITED

M. Pierotti, G. Parmiani, 1984, Journal of immunogenetics.

Allostimulation-induced tumor cytotoxic cells: from mouse to man.

G. Parmiani, M. Sensi, G. Fossati, 1985, Immunology today.

Eradication of a disseminated mouse lymphoma by 1,3‐BIS(2‐chloroethyl)‐1‐nitrosourea is immunologically mediated and accompanied by de novo generation of anti‐tumor cytotoxicity

F. Formelli, G. Parmiani, M. Sensi, 1990, International journal of cancer.

Tumor-associated alien alloantigens of BALB/c tumors encoded by the MHC and by non-H-2 genes: a histogenetic study.

D. Ballinari, G. Parmiani, M. Sensi, 1980, Journal of immunology.

In Vivo Inhibition of Antitumor Immunity by Embryonic Antigens

G. Parmiani, R. Lembo, 1976, Tumori.

Advances in Brief Heterogeneity in Human Melanoma Cell Adhesion to Cytokine Activated Endothelial Cells Correlates with VLA-4 Expression 1

A. Mantovani, S. Bernasconi, F. Sánchez‐Madrid, 2006 .

Effect of anti‐embryo immunization on methylcholanthrene‐induced sarcoma growth in BALB/c mice

G. Parmiani, R. Lembo, 1974, International journal of cancer.

Immunodepression During Urethane and N-Nitrosomethylurea Leukaemogenesis in Mice

G. Parmiani, M. Colnaghi, G. Porta, 1971, British Journal of Cancer.

Skin-graft rejection during lymphomagenesis in urethan-treated mice.

G. Parmiani, 1971, Journal of the National Cancer Institute.

Jmmunodepressive and Leukemogenic Effects of Urethan in C3Hf and SWR Mice∗

G. Parmiani, M. Colnaghi, G. Porta, 1969, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

Effects of antitumour immunity on pregnancy in the mouse.

G. Parmiani, G. Porta, G. Della Porta, 1973, Nature: New biology.

Future perspectives in melanoma research: meeting report from the “Melanoma Bridge”: Napoli, December 3rd–6th 2014

Martin F. Mihm, B. Schilling, F. Marincola, 2013, Journal of Translational Medicine.

TCR beta-chain variable region-driven selection and massive expansion of HLA-class I-restricted antitumor CTL lines from HLA-A*0201+ melanoma patients.

C. Farina, A. Anichini, G. Parmiani, 1997, Journal of immunology.

Immunobiological Characterization of Cancer Stem Cells Isolated from Glioblastoma Patients

F. Marincola, R. Galli, E. Wang, 2010, Clinical Cancer Research.

Interleukin-12: Biological Properties and Clinical Application

M. Del Vecchio, M. Lotze, A. Anichini, 2007, Clinical Cancer Research.

Expression of H-2 and viral antigens and resistance to the antitumor lysis of tunicamycin-treated MBL-2 lymphoma cells.

M. Colombo, M. Pierotti, D. Ballinari, 1983, Immunobiology.

Alien histocompatibility antigens on tumor cells

E. Appella, M. Pierotti, G. Parmiani, 1979, Immunogenetics.

Anti-H-2 alloantibodies elicited by syngeneic immunizations with a chemically induced fibrosarcoma

G. Parmiani, A. Meschini, 1978, Immunogenetics.

Inhibition of proliferation by c-myb antisense oligodeoxynucleotides in colon adenocarcinoma cell lines that express c-myb.

M. Colombo, B. Calabretta, G. Parmiani, 1991, Cancer research.

Differential patterns of HOX gene expression are associated with specific integrin and ICAM profiles in clonal populations isolated from a single human melanoma metastasis

M. Cantile, A. Anichini, G. Parmiani, 1996, International journal of cancer.

HOXB7 constitutively activates basic fibroblast growth factor in melanomas

A. Carè, C. Peschle, M. Colombo, 1996, Molecular and cellular biology.

Identification of epitope mimics recognized by CTL reactive to the melanoma/melanocyte-derived peptide MART-1(27-35)

F. Marincola, E. Appella, M. Nishimura, 1996, The Journal of experimental medicine.

Immunomodulating and Immunoresistance Properties of Cancer-Initiating Cells: Implications for the Clinical Success of Immunotherapy

S. Ferrone, G. Parmiani, C. Maccalli, 2017, Immunological investigations.

Integrating Immune Checkpoint Blockade with Anti-Neo/Mutated Antigens Reactivity to Increase the Clinical Outcome of Immunotherapy

M. Maio, G. Parmiani, C. Maccalli, 2015, Vaccines.

Immunology and immunotherapy of colorectal cancer.

P. Dalerba, G. Parmiani, C. Castelli, 2003, Critical reviews in oncology/hematology.

A listing of human tumor antigens recognized by T cells: March 2004 update

G. Parmiani, C. Castelli, Giorgio Parmiani, 2005, Cancer Immunology, Immunotherapy.

A listing of human tumor antigens recognized by T cells

P. Robbins, G. Parmiani, C. Castelli, 2001, Cancer Immunology, Immunotherapy.

Tumour-released exosomes and their implications in cancer immunity

G. Parmiani, S. Fais, L. Rivoltini, 2008, Cell Death and Differentiation.

Mutually exclusive NRASQ61R and BRAFV600E mutations at the single-cell level in the same human melanoma

F. Lozupone, G. Nicolini, A. Anichini, 2006, Oncogene.

BRAF alterations are associated with complex mutational profiles in malignant melanoma

M. Pierotti, S. Pilotti, F. Perrone, 2004, Oncogene.

Vaccination therapy in prostate cancer

A. Marrari, R. Salvioni, G. Parmiani, 2007, Cancer Immunology, Immunotherapy.

Somatically mutated tumor antigens in the quest for a more efficacious patient-oriented immunotherapy of cancer

Z. Trajanoski, G. Parmiani, P. Dellabona, 2014, Cancer Immunology, Immunotherapy.

Cytokine gene transduction in the immunotherapy of cancer.

M. Colombo, G. Parmiani, C. Melani, 1997, Advances in pharmacology.

Unique Human Tumor Antigens: Immunobiology and Use in Clinical Trials1

G. Parmiani, C. Castelli, Giorgio Parmiani, 2007, The Journal of Immunology.

Local cytokine availability elicits tumor rejection and systemic immunity through granulocyte-T-lymphocyte cross-talk.

M. Colombo, G. Forni, A. Modesti, 1992, Cancer research.

Human NK Cells Selective Targeting of Colon Cancer–Initiating Cells: A Role for Natural Cytotoxicity Receptors and MHC Class I Molecules

Rosanna La Rocca, Klas Kärre, Luca Tirinato, 2013, The Journal of Immunology.

Targeting TNF-α to Neoangiogenic Vessels Enhances Lymphocyte Infiltration in Tumors and Increases the Therapeutic Potential of Immunotherapy

A. Corti, F. Curnis, A. Mondino, 2012, The Journal of Immunology.

Naturally occurring peptides associated with HLA-A2 in ovarian cancer cell lines identified by mass spectrometry are targets of HLA-A2-restricted cytotoxic T cells.

L. Karns, R. Kiessling, G. Parmiani, 2003, International immunology.

Self-adjuvanted mRNA vaccination in advanced prostate cancer patients: a first-in-man phase I/IIa study

K. Miller, W. Schultze‐Seemann, A. Stenzl, 2015, Journal of Immunotherapy for Cancer.

Growth Characteristics of Human Colorectal and Non-Small Cell Lung Tumors Xenografted into Nude Mice: Possible Correlation with Prognosis

R. Doci, G. Pezzoni, G. Parmiani, 1986, Tumori.

A merging duo in melanoma formation.

M. Pierotti, G. Parmiani, M. Rodolfo, 2005, The Journal of investigative dermatology.

CD4 T cells inhibit in vivo the CD8‐mediated immune response against murine colon carcinoma cells transduced with interleukin‐12 genes

G. Trinchieri, M. Colombo, A. Stoppacciaro, 1995, European journal of immunology.

Heat shock proteins: biological functions and clinical application as personalized vaccines for human cancer

Alessandro Testori, Pramod K. Srivastava, Licia Rivoltini, 2004, Cancer Immunology, Immunotherapy.

Tumor-infiltrating lymphocytes: their phenotype, functions and clinical use

T. Whiteside, G. Parmiani, Giorgio Parmiani, 1994, Cancer Immunology, Immunotherapy.

Consensus nomenclature for CD 8 T cell phenotypes in cancer

S. H. van der Burg, J. Blay, F. Marincola, 2015 .

Non-carcinogenicity of hexamethylenetetramine in mice and rats.

G. Parmiani, M. Colnaghi, G. Della Porta, 1968, Food and cosmetics toxicology.

Regression of an established tumor genetically modified to release granulocyte colony-stimulating factor requires granulocyte-T cell cooperation and T cell-produced interferon gamma

M. Colombo, A. Stoppacciaro, G. Parmiani, 1993, The Journal of experimental medicine.

Tumour immunotherapy: the adjuvant treatment of the 21st century?

P. Kuppen, G. Parmiani, A. Bremers, 2000, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Interferon adjuvant to radical nephrectomy in Robson stages II and III renal cell carcinoma: a multicentric randomized study.

P. Boracchi, E. Marubini, L. Piva, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

HLA Binding Characteristics and Generation of Cytotoxic Lymphocytes against Peptides Derived from Oncogenic Proteins

G. Parmiani, C. Gambacorti-Passerini, F. Ravagnani, 1997, Tumori.

Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial.

P. Ascierto, A. Testori, E. Simeone, 2012, The Lancet. Oncology.

Immunology of cancer stem cells in solid tumours. A review.

G. Parmiani, C. Maccalli, C. Cimminiello, 2014, European journal of cancer.

Immunological approach to gene therapy of human cancer: improvements through the understanding of mechanism(s)

G. Parmiani, 1998, Gene Therapy.

Escape strategies and reasons for failure in the interaction between tumour cells and the immune system: how can we tilt the balance towards immune-mediated cancer control?

F. Lozupone, G. Parmiani, S. Fais, 2005, Expert opinion on biological therapy.

Gene therapy of melanoma

P. Dalerba, G. Parmiani, 2003 .

Surgical Treatment of Melanoma: A Survey of Italian Hospitals

I. Stanganelli, A. Testori, V. Chiarion-Sileni, 2013, Dermatology.

Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: the C-100-21 Study Group.

Axel Hoos, Alessandro Testori, Jon Richards, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

High frequency of T cell clonal expansions in primary human melanoma. Involvement of a dominant clonotype in autologous tumor recognition

A. Anichini, G. Parmiani, R. Mortarini, 1999, Cancer Immunology, Immunotherapy.

Intralesional selection of T cell clonotypes in the immune response to melanoma antigens occurring during vaccination.

C. Farina, A. Anichini, G. Parmiani, 1998, Journal of immunotherapy.

Conserved TCR usage by HLA-Cw* 1601-restricted T cell clones recognizing melanoma antigens.

C. Farina, G. Parmiani, P. van der Bruggen, 1996, International immunology.

Chromosomal changes associated with urethan leukemogenesis in mice

G. Parmiani, M. Colnaghi, G. Porta, 1969, International journal of cancer.

Human dendritic cells: natural adjuvants in antitumor immunotherapy.

A. Anichini, M. Di Nicola, G. Parmiani, 1998, Cytokines, cellular & molecular therapy.

Heterogeneity for integrin expression and cytokine‐mediated VLA modulation can influence the adhesion of human melanoma cells to extracellular matrix proteins

A. Anichini, G. Parmiani, R. Mortarini, 1991, International journal of cancer.

Resistance of Cancer Stem Cells to Cell-Mediated Immune Responses

G. Stassi, G. Parmiani, C. Maccalli, 2015 .

Analysis of TCR usage in human tumors: a new tool for assessing tumor-specific immune responses.

G. Parmiani, M. Sensi, 1995, Immunology today.

LACK OF H‐2Ld LOCUS PRODUCTS ON A BALB/c FIBROSARCOMA EXPRESSING H‐2k‐LIKE ALIEN ANTIGENS

M. Pierotti, D. Ballinari, G. Parmiani, 1983, Journal of immunogenetics.

Histocompatibility antigens and tumour antigens

G. Parmiani, 1980, Cancer Immunology, Immunotherapy.

Peptides derived from self-proteins as partial agonists and antagonists of human CD8+ T-cell clones reactive to melanoma/melanocyte epitope MART1(27-35).

E. Appella, C. Geisler, G. Parmiani, 1998, Cancer research.

Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going?

Francesco M Marincola, Licia Rivoltini, Piero Dalerba, 2002, Journal of the National Cancer Institute.

An Expanded Peripheral T Cell Population to a Cytotoxic T Lymphocyte (Ctl)-Defined, Melanocyte-Specific Antigen in Metastatic Melanoma Patients Impacts on Generation of Peptide-Specific Ctls but Does Not Overcome Tumor Escape from Immune Surveillance in Metastatic Lesions

V. Cerundolo, S. Pilotti, A. Anichini, 1999, The Journal of experimental medicine.

Pre-clinical and clinical aspects of peptide-based vaccine against human solid tumors.

G. Parmiani, S. Jalali, 2011, Recent patents on biotechnology.

Local Adoptive Immunotherapy of Advanced Head and Neck Tumors with Lak Cells and Interleukin-2

G. Parmiani, F. Ravagnani, L. Rivoltini, 1990, Tumori.

Awareness and understanding of cancer immunotherapy in Europe

I. Melero, H. Mellstedt, N. Thatcher, 2014, Human vaccines & immunotherapeutics.

Alien H-2 antigens (H-2k) appearing on a methylcholanthrene-induced tumor (H-2d): biochemical characterization.

E. Appella, M. Pierotti, G. Parmiani, 1980, Transplantation proceedings.

Preparation of antigenically active membranes from solid murine lymphomas and fibrosarcomas.

M. Pierotti, G. Parmiani, G. D. Torre, 1979, Journal of immunological methods.

Biochemical characterization of alien H-2 antigens expressed on a methylcholanthrene-induced tumor.

E. Appella, M. Pierotti, G. Parmiani, 1979, Proceedings of the National Academy of Sciences of the United States of America.

Immunogenic strength of sarcomas induced by methylcholanthrene in millipore filter diffusion chambers.

G. Parmiani, R. Lembo, G. Carbone, 1973, Cancer research.

Genetic control of in vivo immunity to tumor‐specific transplantation antigens of chemically induced murine fibrosarcomas

D. Ballinari, G. Parmiani, 1979, International journal of cancer.

Tumor-associated transplantation antigen distinct from H-2k-like antigens on a BALB/c (H-2d) fibrosarcoma.

G. Parmiani, A. Meschini, G. Invernizzi, 1978, Journal of the National Cancer Institute.

Successful adoptive immunotherapy with lymphokine-activated killer cells in the treatment of medulloblastoma disseminated via cerebrospinal fluid: case report.

A. Silvani, A. Salmaggi, G. Parmiani, 1994, Neurosurgery.

Tumor-infiltrating T cells--friend or foe of neoplastic cells?

G. Parmiani, 2005, The New England journal of medicine.

Awareness and understanding of cancer immunotherapy in Europe.

I. Melero, H. Mellstedt, N. Thatcher, 2013 .

Follow-Up of Melanoma: A Survey of Italian Hospitals

I. Stanganelli, A. Testori, V. Chiarion-Sileni, 2013, Dermatology.

Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programme

P. Ascierto, A. Testori, P. Queirolo, 2014, Journal of experimental & clinical cancer research : CR.

Human colorectal cancer cells induce T-cell death through release of proapoptotic microvesicles: role in immune escape.

G. Parmiani, S. Fais, E. Seregni, 2005, Gastroenterology.

Autologous tumor-derived HSPPC-96 vs. physician's choice (PC) in a randomized phase III trial in stage IV melanoma.

A. Testori, P. Srivastava, L. Camacho, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Role of Cross-Talk between IFN-α-Induced Monocyte-Derived Dendritic Cells and NK Cells in Priming CD8+ T Cell Responses against Human Tumor Antigens1

F. Belardelli, G. Parmiani, L. Rivoltini, 2004, The Journal of Immunology.

Vaccination with autologous tumor-derived heat-shock protein gp96 after liver resection for metastatic colorectal cancer.

Jonathan J. Lewis, L. Mariani, V. Mazzaferro, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Italian cohort of ipilimumab expanded access programme (EAP): Efficacy, safety, and correlation with mutation status in metastatic melanoma patients.

P. Ascierto, E. Simeone, P. Queirolo, 2013 .

Correlation between efficacy and toxicity in pts with pretreated advanced melanoma treated within the Italian cohort of the ipilimumab expanded access programme (EAP).

P. Ascierto, A. Testori, P. Queirolo, 2013 .

Induction of Both CD8+ and CD4+ T-Cell–Mediated Responses in Colorectal Cancer Patients by Colon Antigen-1

M. Tartaglia, V. Zagonel, F. Belardelli, 2008, Clinical Cancer Research.

T cell infiltration and prognosis in HCC patients.

A. Anichini, G. Parmiani, 2006, Journal of hepatology.

Interleukin 12 potentiates the curative effect of a vaccine based on interleukin 2-transduced tumor cells.

M. Colombo, G. Forni, G. Parmiani, 1996, Cancer research.

Natural Cytotoxicity Receptors and MHC Initiating Cells : A Role for − Colon Cancer Human NK Cells Selective Targeting of Dieli

M. Todaro, G. Stassi, E. Fabrizio, 2013 .

Boosting T Cell-Mediated Immunity to Tyrosinase by Vaccinia Virus-Transduced, CD34+-Derived Dendritic Cell Vaccination

M. Del Vecchio, N. Cascinelli, A. Anichini, 2004, Clinical Cancer Research.

What is new in melanoma research? Vaccines, Basic and Translational Research in 2003: report of a workshop at the Third Research Meeting on Melanoma, Milan, Italy, May 2003

A. Testori, M. Rescigno, G. Parmiani, 2004, Melanoma research.

Treatment of recurrent in transit metastases from cutaneous melanoma by isolation perfusion in extracorporeal circulation with interleukin‐2 and lymphokine activated killer cells. A pilot study

N. Cascinelli, M. Ammatuna, G. Parmiani, 1992, Melanoma research.

Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings.

Jonathan J. Lewis, A. Testori, P. Queirolo, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

V a c c ination o f M etastatic M elanoma P atients W ith Autologous T umor-Derived H eat S hock P rotein g p96- Peptide C omplexes: C linical a nd I mmunologic F indings

Jonathan J. Lewis, A. Testori, P. Queirolo, 2002 .

Active immunization of metastatic melanoma patients with interleukin-2-transduced allogeneic melanoma cells: evaluation of efficacy and tolerability

M. Colombo, N. Cascinelli, A. Cattelan, 1997, Cancer Immunology, Immunotherapy.

A clinical development paradigm for cancer vaccines and related biologics.

A. Eggermont, M. Sznol, W. Urba, 2007, Journal of immunotherapy.

T-cell response to unique and shared antigens and vaccination of cancer patients.

A. Anichini, G. Parmiani, C. Castelli, 2002, Cancer immunity.

Detection of mutated BRAFV600E variant in circulating DNA of stage III–IV melanoma patients

M. Pierotti, G. Parmiani, M. Daniotti, 2007, International journal of cancer.

11 Recent developments of immunotherapy in melanoma patients.The experience of Milano National Cancer Institute

N. Cascinelli, G. Parmiani, F. Belli, 1997 .

Frequency of CTL precursors and effectors directed to a single peptide of melan-A/Mart-1: Evidence for heterogeneity among HLA-A*0201+melanoma patients

A. Anichini, G. Parmiani, A. Molla, 1997 .

Cytokine-mediated modulation of HLA-class II, ICAM-1, LFA-3 and tumor-associated antigen profile of melanoma cells. Comparison with anti-proliferative activity by rIL1-beta, rTNF-alpha, rIFN-gamma, rIL4 and their combinations.

A. Anichini, G. Parmiani, R. Mortarini, 1990, International journal of cancer.

Binding and presentation of peptides derived from melanoma antigens MART-1 and glycoprotein-100 by HLA-A2 subtypes. Implications for peptide-based immunotherapy.

F. Marincola, E. Appella, M. Salgaller, 1996, Journal of immunology.

Update on vaccines for melanoma patients

G. Parmiani, S. Mercuri, C. Maccalli, 2008 .

Peptide-based vaccines for cancer therapy

M. Maio, G. Parmiani, C. Maccalli, 2014, Human vaccines & immunotherapeutics.

Tumor rejection activity of antigens isolated from the membranes of a methylcholanthrene-induced sarcoma, C-1, bearing alien H-2 antigens.

E. Appella, M. Pierotti, G. Parmiani, 1980, Transplantation proceedings.

Immunohistochemical analysis of the T-cell receptor beta-chain variable regions expressed by T lymphocytes infiltrating primary human melanoma.

M. Mihm, G. Parmiani, I. Bersani, 1998, Laboratory investigation; a journal of technical methods and pathology.

Ex vivo enrichment of circulating anti-tumor T cells from both cutaneous and ocular melanoma patients: clinical implications for adoptive cell transfer therapy

C. Doglioni, G. Parmiani, C. Maccalli, 2011, Cancer Immunology, Immunotherapy.

PHENOTYPIC HETEROGENEITY OF HLA PRODUCTS ON HUMAN MELANOMA CELLS

D. Taramelli, N. Cascinelli, S. Andreola, 1986, Journal of immunogenetics.

Heterogeneity of clones from a human metastatic melanoma detected by autologous cytotoxic T lymphocyte clones

A. Anichini, G. Parmiani, G. Fossati, 1986, The Journal of experimental medicine.

Active immunization of metastatic melanoma patients with IL-2 or IL-4 gene transfected, allogeneic melanoma cells.

M. Colombo, N. Cascinelli, G. Parmiani, 1998, Advances in experimental medicine and biology.

Multipeptide vaccination in cancer patients

A. Marrari, G. Parmiani, R. Valdagni, 2009, Expert opinion on biological therapy.

Immunogenicity of the ALLAVGATK (gp10017 – 25) peptide in HLA‐A3.1 melanoma patients

M. Maio, G. Parmiani, C. Castelli, 1998, European journal of immunology.

Lack of terminally differentiated tumor-specific CD8+ T cells at tumor site in spite of antitumor immunity to self-antigens in human metastatic melanoma.

N. Cascinelli, C. Bartoli, C. Lombardo, 2003, Cancer research.

Melanoma: The Milan Melanoma Cell Lines

A. Anichini, G. Parmiani, A. Molla, 2002 .

T cell receptor (TCR) structure of autologous melanoma-reactive cytotoxic T lymphocyte (CTL) clones: tumor-infiltrating lymphocytes overexpress in vivo the TCR beta chain sequence used by an HLA-A2- restricted and melanocyte-lineage-specific CTL clone

M. Herlyn, G. Nicolini, A. Anichini, 1993, The Journal of experimental medicine.

Identification of a novel gp100/pMel17 peptide presented by HLA-A*6801 and recognized on human melanoma by cytolytic T cell clones.

G. Nicolini, A. Anichini, S. Pellegatta, 2002, Tissue antigens.

Cytokines in cancer therapy.

G. Parmiani, L. Rivoltini, M. Carrabba, 2000, Immunology letters.

Selective Histocompatibility Leukocyte Antigen (Hla)-A2 Loss Caused by Aberrant Pre-mRNA Splicing in 624mel28 Melanoma Cells

F. Marincola, S. Ferrone, G. Parmiani, 1999, The Journal of experimental medicine.

Microenvironment and Immunology Modulation of Microenvironment Acidity Reverses Anergy in Human and Murine Tumor-In fi ltrating T Lymphocytes

R. Canese, G. Parmiani, S. Fais, 2012 .

Non-Redundant Role for IL-12 and IL-27 in Modulating Th2 Polarization of Carcinoembryonic Antigen Specific CD4 T Cells from Pancreatic Cancer Patients

M. Braga, R. Longhi, G. Parmiani, 2009, PloS one.

Clinical and immunologic responses in melanoma patients vaccinated with MAGE‐A3‐genetically modified lymphocytes

F. Fazio, L. Gianolli, P. Coulie, 2013, International journal of cancer.

Control of human melanoma growth in nude mice by autologous allo‐activated peripheral blood lymphocytes

M. Colombo, G. Parmiani, A. Balsari, 1986, International journal of cancer.

Can oncogene (RAS) activation predict susceptibility of human melanoma to activated lymphocytes and, therefore, the clinical response of such neoplasms to adoptive immunotherapy?

A. Anichini, G. Parmiani, M. Sensi, 1992, Melanoma research.

CEA and NCA Expressed by Colon Carcinoma Cells Affect their Interaction with and Lysability by Activated Lymphocytes

G. Cattoretti, G. Parmiani, A. Mastroianni, 1992, The International journal of biological markers.

Increased susceptibility to lymphokine activated killer (LAK) lysis of relapsing vs. newly diagnosed acute leukemic cells without changes in drug resistance or in the expression of adhesion molecules.

G. Parmiani, C. Gambacorti-Passerini, L. Rivoltini, 1992, Annals of oncology : official journal of the European Society for Medical Oncology.

Universal and Stemness-Related Tumor Antigens: Potential Use in Cancer Immunotherapy

A. Marrari, G. Parmiani, C. Castelli, 2007, Clinical Cancer Research.

β1-Integrins on Melanoma Clones Regulate the Interaction with Autologous Cytolytic T-Cell Clones

A. Anichini, G. Parmiani, R. Mortarini, 1992 .

Heat shock proteins gp96 as immunogens in cancer patients

G. Parmiani, C. Castelli, L. Rivoltini, 2006, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.

Sensi M, Nicolini G, Petti C, Bersani I, Lozupone F, Molla A et al.. Mutually exclusive NRASQ61R and BRAFV600E mutations at the single-cell level in the same human melanoma. Oncogene 25: 3357-3364

F. Lozupone, G. Nicolini, A. Anichini, 2006 .

Inhibition of Human Melanoma Growth in Nude Mice by Autologous, Alloactivated Peripheral Blood Lymphocytes

D. Taramelli, G. Parmiani, A. Balsari, 1984, Tumori.

Multiple melanoma-associated epitopes recognized by HLA-A3-restricted CTLs and shared by melanomas but not melanocytes.

A. Anichini, G. Parmiani, M. Maeurer, 1996, Journal of immunology.

Differentiation of CD8+ T Cells from Tumor-Invaded and Tumor-Free Lymph Nodes of Melanoma Patients: Role of Common γ-Chain Cytokines1

A. Anichini, G. Parmiani, A. Molla, 2003, The Journal of Immunology.

T cell-defined melanoma antigens: toward a tumour-specific immunotherapy of the disease.

G. Parmiani, 1993, Melanoma research.

Interleukin-2 biology and immunology

G. Parmiani, C. Gambacorti-Passerini, 1993 .

Immunogenic Neoplastic Clones Derived in Vitro from an Originally Non-immunogenic BALB/c Fibrosarcoma 1

G. Parmiani, G. Carbone, 1977, Tumori.

Chain Cytokines γ Common Nodes of Melanoma Patients : Role of Tumor-Invaded and Tumor-Free Lymph T Cells from + Differentiation of CD 8 Parmiani and

A. Anichini, G. Parmiani, A. Molla, 2003 .

N-RAS mutations and susceptibility to lymphokine-activated killer (LAK) cells in human melanoma

A. Anichini, G. Parmiani, R. Mortarini, 1994, Melanoma research.

Tumorigenicity and dissemination of primary and metastatic human melanomas implanted into different sites in athymic nude mice.

G. Parmiani, M. Rodolfo, A. Balsari, 1988, Invasion & metastasis.

Activation of ras oncogenes and expression of tumor‐specific transplantation antigens in methylcholanthrene‐induced murine fibrosarcomas

M. Borrello, M. Pierotti, G. Parmiani, 1991, International journal of cancer.

Immunomodulation in a Treatment Program Including Pre- and Post-Operative Interleukin-2 and Chemotherapy for Childhood Osteosarcoma

A. Ferrari, M. Massimino, G. Parmiani, 2003, Tumori.

GVHR with anti-tumour lymphocytes 179

G. Parmiani, G. Invernizzi, 2007 .

Genetic control of responsiveness to the tumor-associated transplantation antigen of a chemically induced murine fibrosarcoma

G. Parmiani, 1978, Immunogenetics.

COINCIDENT EFFECT IN THE GRAFT‐VERSUS‐HOST REACTION OF BALB/c LYMPHOID CELLS DERIVED FROM MICE IMMUNE EITHER TO ALLOGENEIC NORMAL TISSUE OR TO SYNGENEIC CHEMICALLYINDUCED FIBROSARCOMATA

G. Parmiani, G. Invernizzi, 1977 .

Effect of different sera on growth and "spontaneous" neoplastic transformation of mouse fibroblasts in vitro.

G. Parmiani, R. Piazza, G. Carbone, 1974, Journal of the National Cancer Institute.

Adoptive immunotherapeutic treatments with interleukin 2 and lymphocytes in a mouse colonic adenocarcinoma model.

G. Parmiani, M. Rodolfo, M. Sensi, 1990, Annali dell'Istituto superiore di sanita.

Cannibalism of live lymphocytes by human metastatic but not primary melanoma cells.

Licia Rivoltini, Massimo Gentile, Stefano Fais, 2006, Cancer research.

T cell neoepitope discovery in colorectal cancer by high throughput profiling of somatic mutations in expressed genes

M. Severgnini, M. Braga, J. Sidney, 2015, Gut.

N-Nitroso Compounds in the Environment.

G. Parmiani, 1975 .

Defective T helper activity in the spleen of BALB/c mice immune to a syngeneic fibrosarcoma

L. Grazioli, G. Parmiani, M. Sensi, 2004, Cancer Immunology, Immunotherapy.

Genes involved in melanoma: an overview of INK4a and other loci.

M. Castellano, G. Parmiani, 1999, Melanoma research.

Heterogeneous phenotype of human melanoma cells with in vitro and in vivo features of tumor-initiating cells.

L. Mariani, M. Daidone, A. Villa, 2010, The Journal of investigative dermatology.

In vitro "spontaneous" neoplastic transformation of mouse fibroblasts in diffusion chambers.

G. Parmiani, R. Prehn, G. Carbone, 1971, Journal of the National Cancer Institute.

Granulocyte colony-stimulating factor (G-CSF) gene transduction in murine adenocarcinoma drives neutrophil-mediated tumor inhibition in vivo. Neutrophils discriminate between G-CSF-producing and G-CSF-nonproducing tumor cells.

M. Colombo, A. Stoppacciaro, G. Parmiani, 1992, Journal of immunology.

Expression of retrovirus-related, cytotoxic T lymphocyte- and transplantation-defined antigens in NIH/3T3 transfectants after a single passage in nude mice.

G. Parmiani, C. Traversari, M. Sensi, 1989, Journal of immunology.

Syngeneic Antitumor and Antiembryo Immunization Affecting Pregnancy in Mice 1

G. Parmiani, Rosario Lembo, 1976, Tumori.

Conference on cancer vaccines

D. Schadendorf, M. Colombo, F. Belardelli, 2000, Cancer Immunology, Immunotherapy.

Preliminary results of contrast‐enhanced sonography in the evaluation of the response of uveal melanoma to gamma‐knife radiosurgery

A. Del Maschio, G. Parmiani, F. Bandello, 2015, Journal of clinical ultrasound : JCU.

ORIGINAL H‐2d AND FOREIGN H ‐ 2k ‐ LIKE ANTIGENS ARE INDEPENDENT ENTITIES ON A CHEMICALLY INDUCED SARCOMA

D. Ballinari, G. Parmiani, A. Meschini, 1978, Journal of immunogenetics.

Immune landscape and in vivo immunogenicity of NY-ESO-1 tumor antigen in advanced neuroblastoma patients

G. Parmiani, P. Collini, R. Luksch, 2018, BMC Cancer.

DEPRESSION OF CELLULAR IMMUNE RESPONSE DURING SYNGENEIC PREGNANCY AS MEASURED BY THE GRAFT‐VERSUS-HOST REACTION

G. Parmiani, G. Invernizzi, 1975, Transplantation.

Simultaneous transduction of B7-1 and IL-2 genes into human melanoma cells to be used as vaccine: enhancement of stimulatory activity for autologous and allogeneic lymphocytes

M. Colombo, M. Del Vecchio, C. Lombardo, 2001, Cancer Immunology, Immunotherapy.

Cancer vaccination.

M. Del Vecchio, G. Parmiani, 1999, Forum.

Immunotherapy for colon cancer.

G. Parmiani, A. Bremers, 1999, The Lancet.

Effect of human natural killer and gammadelta T cells on the growth of human autologous melanoma xenografts in SCID mice.

F. Lozupone, F. Belardelli, G. Parmiani, 2004, Cancer research.

A randomized, phase III study of fotemustine versus the combination of fotemustine and ipilimumab or the combination of ipilimumab and nivolumab in patients with metastatic melanoma with brain metastasis: the NIBIT-M2 trial.

P. Ascierto, P. Queirolo, M. Mandalà, 2015 .

Cytokine gene transduction in tumor cells: interleukin (IL)-2 or IL-4 gene transfer in human melanoma cells.

M. Colombo, A. Anichini, J. Sulé-Suso, 1994, Natural immunity.

Tumor-Derived Exosomes as Dendritic Cell Modulators

G. Parmiani, L. Rivoltini, P. Filipazzi, 2009 .

Expression of alien minor histocompatibility antigens distinct from tumor‐specific transplantation antigen on a murine fibrosarcoma

D. Ballinari, G. Parmiani, Giorgio Parmiani, 1980, International journal of cancer.

In vitro and in vivo expression of original and foreign H‐2 antigens and of the tumor‐associated transplantation antigen of a murine fibrosarcoma

G. Parmiani, A. Meschini, G. Invernizzi, 1978, International journal of cancer.

A phase II study combining ipilimumab and fotemustine in patients with metastatic melanoma: The NIBIT-M1 trial.

P. Ascierto, A. Testori, P. Queirolo, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cytotoxic T lymphocytes recognize tumor antigens of a murine colonic carcinoma by using different T‐cell receptors

G. Parmiani, M. Rodolfo, C. Castelli, 1994, International journal of cancer.

Granulocyte colony-stimulating factor gene transfer suppresses tumorigenicity of a murine adenocarcinoma in vivo

M. Colombo, A. Stoppacciaro, G. Parmiani, 1991, The Journal of experimental medicine.

Lack of anti-TSTA antibodies in mice immunized with a methylcholanthrene-induced fibrosarcoma

M. Boiocchi, G. Parmiani, G. Carbone, 1981, Cancer Immunology, Immunotherapy.

FREQUENCY OF CYTOTOXIC T LYMPHOCYTE PRECURSORS (CTLp) RECEPTOR: LIMITING DILUTION ANALYSIS OF SPECIFIC CTLp OF MELANOMA PATIENTS INTERACTING WITH AUTOLOGOUS TUMOR VIA THE T-CELL IN PERIPHERAL BLOOD AND TUMOR-INVADED LYMPH NODES

G. Parmiani, C. Vegetti, A. Mazzocchi, 2006 .

Immune landscape and in vivo immunogenicity of NY-ESO-1 tumor antigen in advanced neuroblastoma patients

G. Parmiani, P. Collini, R. Luksch, 2018, BMC Cancer.

Limitations of the cancer stem cell theory

G. Parmiani, Giorgio Parmiani, Luca Vezzoni, 2008, Cytotechnology.

Future perspectives in melanoma research: meeting report from the “Melanoma Bridge”: Napoli, December 3rd–6th 2014

Martin F. Mihm, B. Schilling, F. Marincola, 2013, Journal of Translational Medicine.

Two autologous melanoma-specific and MHC-restricted human T cell clones with identical intra-tumour reactivity do not share the same TCR V alpha and V beta gene families.

A. Anichini, G. Parmiani, R. Mortarini, 1991, Melanoma research.

Soluble NKG2D ligands are biomarkers associated with the clinical outcome to immune checkpoint blockade therapy of metastatic melanoma patients

F. Marincola, D. Bedognetti, M. Maio, 2017, Oncoimmunology.

Therapeutic vaccines for cancer: an overview of clinical trials

I. Melero, H. Mellstedt, N. Thatcher, 2014, Nature Reviews Clinical Oncology.

DIFFERENTIAL LYSIS OF MELANOMA CLONES BY AUTOLOGOUS RECOMBINANT SPONTANEOUS RESISTANCE TO DOXORUBICIN (Dx) INTERLEUKIN 2-ACTIVATED LYMPHOCYTES. RELATIONSHIP WITH

G. Parmiani, C. Gambacorti-Passerini, Licia RIVOLTW', 2006 .

C. Farina, G. Nicolini, A. Anichini, 1998, The Journal of experimental medicine.

Histocompatibility Antigens on the Cell Surface of Tumors

G. Parmiani, G. Porta, 1983 .

H‐2K RESTRICTION OF THE T CELL‐MEDIATED LYSIS OF A CHEMICALLY‐INDUCED BALB/c FIBROSARCOMA

G. Parmiani, M. Rodolfo, M. Colombo, 1983, Journal of immunogenetics.

Original H‐2d and alien H‐2k‐like antigens of a BALB/c fibrosarcoma as defined by in vitro and in vivo studies of cell‐mediated immunity

G. Parmiani, M. Sensi, G. Carbone, 1980, European journal of immunology.

Alien H-2 Antigens on a Chemically Induced Fibrosarcoma: Further Evidence in Crude Membrane and Soluble Extracts of the Tumor

M. Pierotti, G. Parmiani, S. Miotti, 1979, Tumori.

Alien histocompatibility determinants on the cell surface of sarcomas induced by methylcholanthrene. I. In vivo studies

G. Parmiani, G. Invernizzi, Giorgio Parmiani, 1975, International journal of cancer.

Coincedent effect in the graft-versus-host reaction of BALB/c lymphoid cells derived from mice immune either to allogeneic normal tissue or to syngeneic chemically induced fibrosarcomata.

G. Parmiani, G. Invernizzi, 1977, Journal of immunogenetics.

Inhibition of the YC8 lymphoma growth by alloimmunization with normal cells.

G. Parmiani, M. Sensi, 1981, Transplantation proceedings.

In Vivo and in Vitro Methylcholanthrene Carcinogenesis in Diffusion Chambers 1

G. Parmiani, R. Prehn, G. Carbone, 1972, Tumori.

Beta 1-integrins on melanoma clones regulate the interaction with autologous cytolytic T-cell clones.

A. Anichini, G. Parmiani, R. Mortarini, 1992, Journal of immunotherapy : official journal of the Society for Biological Therapy.